BioInvent Q1: Making steady progress, key readouts ahead
BioInvent reported Q1'25 results which mainly focused on balance sheet items and a recap of corporate achievements for the quarter, with opex roughly in line with our estimates at SEK(144.8m) (runway mid-2026). Importantly, several key upcoming catalysts have been reiterated for mid-2025 on both le
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.